WR-1065 dihydrochloride 可通过 JNK 依赖性信号通路激活 p53。它还可以保护正常组织免受某些抗癌药物的毒性作用。

WR-1065 dihydrochloride can activate p53 through a JNK-dependent signaling pathway. It also protects normal tissues from the toxic effects of certain cancer drugs.

The DNA-binding activity is increased in a WR-1065 concentration-dependent manner. Cells treated with 1 mM WR-1065 dihydrochloride for 24 h revealed that all of the p53-induced genes analyzed are transactivated following WR-1065 dihydrochloride treatment, in a p53-dependent manner. Significantly, treatment with WR-1065 dihydrochloride leads to a 3-fold increase in luciferase expression driven by AP-1 and a 5-fold increase when this reporter gene is driven by NF-κB when these values are normalized to the level of the cotransfected β-galactosidase gene [2].

WR-1065 attenuates the severity of 6-OHDA-induced catalepsy when compared with 6-OHDA-lesioned rats. Also, it has been observed that WR-1065 dihydrochloride improves catalepsy in a dose-dependent manner. Pretreatment with three different doses of WR-1065 dihydrochloride (20, 40, and 80 μg/2 μL/rat) for 3 days before 6-OHDA administration, significantly elevates SOD activity and restores it to normal range compare with 6-OHDA lesioned rats [3].

For Western analysis, cells are treated with 1 mM WR-1065 for 24 h, and subconfluent cultures of cells are harvested and lysed in RIPA buffer supplemented with protease inhibitors. Protein concentrations are determined by a detergent-compatible assay. Western blots are blocked and incubated in antibody in PBS/0.2% Tween 20/5% nonfat dry milk. Blots are incubated with 1 μg/mL antibody for 1 h at room temperature, followed by washing in PBS/0.2% Tween 20 and incubation in peroxidase-conjugated secondary antibody and chemiluminescence detection [2].

Seventy-two rats are divided randomly into 9 equal groups: 1) Control group receives no injection and is left untreated for the entire period of the experiment as intact animals; 2) Sham-operated group is subjected only to surgical procedure; 3) Vehicle (saline)-treated group receives 2 μL saline (Intra-SNc); 4) Lesioned group receives 6-hydroxydopamine; 5) Vehicle+6OHDA group receives saline as a vehicle 3 days once daily (2 μL/rat) before 6-OHDA injection; 6 to 8) Rats in these groups are pretreated with Intra-SNc injection of WR-1065 (20, 40 and 80 μg/2 μL/rat) 3 days before 6-OHDA injection; 9) Non-lesioned animals receive intra-SNc injection of WR-1065 dihydrochloride (80 μg/2 μL/rat) for three days [3].

14653-77-1

C5H16Cl2N2S

207.16

WR 1065;硫代乙基氨基乙基胺盐酸盐

DMSO:24 mg/mL (115.85 mM),Need ultrasonic
H2O:100 mg/mL (482.72 mM)
H2O:100 mg/mL (482.72 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years